Sanofi plays catch-up in immuno-oncology with new Regeneron deal
This article was originally published in Scrip
Executive Summary
With their first collaboration producing the potential blockbuster Praluent and other near-market medicines, Sanofi and Regeneron are likely hoping they can repeat the trick with a new $2bn-deal covering immune-oncology.